Testosterone Enanthate Geriatric (65+) Dosing

Why Geriatric Dosing Differs From Standard Adult Dosing

Men over 65 metabolize testosterone enanthate differently than younger adults. Reduced hepatic clearance, lower lean body mass, and age-related declines in renal function all change drug pharmacokinetics. The clinical goal shifts from maximizing anabolic effect to restoring physiologic levels with the narrowest effective dose.

Age-Related Pharmacokinetic Changes

Glomerular filtration rate drops by approximately 1 mL/min per year after age 40, according to data from the National Kidney Foundation. This matters because testosterone metabolites are partially renally cleared. Hepatic blood flow also declines 20 to 40% by age 65, slowing ester hydrolysis and extending the effective half-life of enanthate. The net result: a given dose produces higher and more prolonged peak concentrations in a 70-year-old than in a 35-year-old.

Body Composition Shifts

Sarcopenia reduces the intramuscular depot volume, which can alter absorption kinetics from IM injections. Fat mass increases with age, and testosterone is lipophilic. These two shifts together mean that standard 200 mg doses designed for younger men often push geriatric patients into supraphysiologic ranges, raising hematocrit and estradiol disproportionately.

The Endocrine Society Position

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with unequivocally low testosterone and clinical symptoms, but flags older men as a population requiring more cautious dosing and closer monitoring. The guideline does not set a hard age cutoff for therapy but specifies that cardiovascular and prostate risk should be weighed individually.

Recommended Starting Doses for Men 65 and Older

The standard adult starting dose for testosterone enanthate is 100 to 200 mg IM every 1 to 2 weeks. For men 65 and older, most clinicians halve the initial dose. This is not an arbitrary reduction.

Typical Initiation Protocol

A common geriatric protocol begins at 50 mg IM weekly or 100 mg IM every two weeks. Both regimens deliver approximately the same weekly amount but differ in peak-to-trough fluctuation. Weekly injections at a lower per-dose volume produce more stable serum levels, which may matter for men sensitive to mood or energy swings between injections.

Titration Schedule

After 4 to 6 weeks, a trough testosterone level (drawn the morning before the next injection) guides dose adjustment. If the trough sits below 350 ng/dL and symptoms persist, an increase of 25 mg per injection is reasonable. The target range for most geriatric patients is 400 to 600 ng/dL. Pushing above 600 ng/dL in men over 75 has no proven additional benefit and increases polycythemia risk, per the T-Trials hematologic findings.

Maximum Dose Considerations

Few geriatric patients need more than 100 mg weekly (equivalent to 200 mg biweekly). If a patient requires doses above 150 mg weekly to reach mid-normal levels, absorption issues, SHBG abnormalities, or non-adherence should be investigated before further escalation.

Evidence From the T-Trials and Other Geriatric Studies

The Testosterone Trials (T-Trials) remain the largest controlled evaluation of testosterone therapy specifically in men 65 and older. Published in the New England Journal of Medicine in 2016, the study enrolled 790 men aged 65 or older with serum testosterone below 275 ng/dL and at least one symptom of hypogonadism.

Key Findings

Participants received testosterone gel (not enanthate), but the physiologic targets and outcomes apply across formulations. After 12 months, testosterone-treated men showed statistically significant improvements in sexual desire (measured by PDQ-Q4, P<0.001), physical activity (6-minute walk distance improved by 33 meters over placebo), and self-reported vitality scores. The gel dose was titrated to reach 400 to 800 ng/dL.

Cardiovascular Signal

A subsequent T-Trials cardiovascular substudy published in JAMA Internal Medicine reported increased coronary artery plaque volume in the testosterone group after 12 months, though the study was not powered for major adverse cardiovascular events (MACE). This finding reinforced the need for cardiovascular risk assessment before prescribing.

The TRAVERSE Trial

The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, was specifically designed to evaluate cardiovascular safety of testosterone in men 45 to 80 with pre-existing cardiovascular disease or high cardiovascular risk. The primary endpoint of MACE showed non-inferiority to placebo (hazard ratio 0.96; 95% CI 0.78 to 1.17). This was the first large trial powered for cardiovascular outcomes and partially allayed the safety concerns raised by earlier studies.

Monitoring Protocol for Older Men on Testosterone Enanthate

Monitoring in geriatric patients is more frequent and broader than in younger men. The stakes are higher: polycythemia can precipitate stroke, PSA rises may mask prostate pathology, and drug interactions multiply with polypharmacy.

Baseline Labs Before Starting

Before the first injection, clinicians should obtain total testosterone (morning draw, fasting), free testosterone or SHBG, complete blood count with hematocrit, PSA, comprehensive metabolic panel, fasting lipid panel, and a DXA scan if osteoporosis is suspected. The American Urological Association guideline recommends two separate morning testosterone readings below 300 ng/dL before diagnosis.

First-Year Monitoring Timeline

Labs should be drawn at 6 weeks, 3 months, 6 months, and 12 months. Every draw should include total testosterone (trough), hematocrit, and PSA. At the 3-month and 12-month marks, add a lipid panel and hepatic function tests. If hematocrit exceeds 54%, the dose should be reduced or therapy held until hematocrit normalizes. This 54% threshold comes directly from the Endocrine Society guideline.

Ongoing Annual Monitoring

After year one, monitoring shifts to every 6 to 12 months if the patient is stable. Annual assessment should include hematocrit, PSA, testosterone level, lipid panel, blood pressure, and a brief symptom review. A digital rectal exam may be appropriate based on individual prostate risk. Men over 75 should have an explicit conversation about continuing therapy at every annual review.

Cardiovascular Risk Management in Geriatric TRT

Cardiovascular disease is the leading cause of death in men over 65. Adding testosterone to this population requires an informed risk-benefit calculation. Testosterone raises hematocrit, which increases blood viscosity. It also affects lipid profiles, typically lowering HDL by 5 to 10%.

Pre-Treatment Cardiovascular Assessment

A resting ECG, blood pressure measurement, and fasting lipid panel should be standard. Men with a history of heart failure (NYHA class III or IV), recent MI within 6 months, or uncontrolled hypertension may not be appropriate candidates. The FDA's 2015 label update added a general warning about possible cardiovascular risk, particularly in men with pre-existing heart disease.

Practical Risk Mitigation

Keep trough testosterone in the 400 to 600 ng/dL window. Higher levels correlate with greater hematocrit rises. Ensure patients stay hydrated, as dehydration amplifies viscosity-related risks. If a patient is on anticoagulation (warfarin, apixaban), monitor INR or anti-Xa levels more frequently during the first 3 months, since testosterone can alter drug metabolism. Patients on dual antiplatelet therapy post-stent should have their cardiologist involved in TRT decision-making.

When to Discontinue for Cardiovascular Reasons

Stop or pause testosterone if hematocrit exceeds 54% on two consecutive draws, if the patient develops new-onset atrial fibrillation, or if they experience a MACE event. Therapeutic phlebotomy is an option for isolated hematocrit elevation, but dose reduction is the preferred first step.

Drug-Drug Interactions in Polypharmacy Patients

The average American over 65 takes 4 to 5 prescription medications. Testosterone enanthate interacts with several drug classes common in geriatric medicine.

Anticoagulants

Testosterone can potentiate warfarin by inhibiting its hepatic metabolism, raising INR and bleeding risk. The package insert carries a specific warning about this interaction. With DOACs like apixaban or rivaroxaban, the interaction is less pronounced but hematocrit-driven viscosity changes still matter clinically.

Insulin and Oral Hypoglycemics

Testosterone improves insulin sensitivity. In men on sulfonylureas or insulin, this can cause hypoglycemia. A 2016 meta-analysis of 15 RCTs found that testosterone therapy reduced fasting glucose by an average of 13 mg/dL and HbA1c by 0.4% in men with type 2 diabetes. Geriatric diabetic patients starting TRT should increase glucose monitoring frequency during the first 8 weeks.

Corticosteroids

Concurrent systemic corticosteroid use (prednisone, dexamethasone) opposes the anabolic effects of testosterone and compounds fluid retention, edema, and hypertension risk. If a geriatric patient requires chronic corticosteroids, lower testosterone enanthate doses and more aggressive blood pressure monitoring are appropriate.

5-Alpha Reductase Inhibitors

Many men over 65 take finasteride or dutasteride for benign prostatic hyperplasia. These drugs reduce dihydrotestosterone (DHT), which may partially blunt the androgenic effects of exogenous testosterone. The combination is not contraindicated, but clinicians should be aware that PSA values will be artificially lowered by approximately 50%, complicating prostate cancer screening. The AUA/ASTRO guideline recommends doubling the reported PSA in patients on 5-alpha reductase inhibitors.

Injection Technique and Practical Considerations for Older Patients

Intramuscular injection technique matters more in geriatric patients. Reduced muscle mass, thinner skin, and anticoagulant use all affect injection safety and comfort.

Site Selection

The ventro-gluteal site remains preferred for IM testosterone injections due to its distance from major nerves and blood vessels. In frail patients with significant gluteal atrophy, the deltoid may be used with a 1-inch, 23- to 25-gauge needle and volumes kept to 1 mL or less per injection. The vastus lateralis is a third option, though post-injection soreness tends to be more pronounced at this site in older adults.

Self-Injection Feasibility

Arthritis, visual impairment, or cognitive decline may prevent safe self-injection. In these cases, caregiver-administered injections or clinic visits are appropriate. Subcutaneous injection of testosterone enanthate (off-label but supported by pharmacokinetic data) using a 27-gauge, 0.5-inch needle is an alternative that some geriatric patients find easier to manage independently.

Storage and Handling

Testosterone enanthate should be stored at 20 to 25°C. The oil-based solution can crystallize at lower temperatures. If visible crystals form, warming the vial in the hands or placing it in warm water for several minutes will redissolve them. Patients should never microwave the vial. Multi-dose vials should be discarded 28 days after first puncture per CDC safe injection guidelines.

When to Consider Stopping or Reducing Therapy

Testosterone replacement is not always a lifetime commitment, especially in older men. Annual reassessment should include both objective labs and a frank discussion about whether the benefits still outweigh the risks.

Deprescribing Triggers

Therapy should be reassessed if the original symptoms have resolved and remain resolved during a supervised dose taper, if new cardiovascular events occur, if PSA velocity exceeds 0.75 ng/mL per year (a signal warranting urologic referral per the AUA), or if the patient develops erythrocytosis that recurs despite dose reduction and phlebotomy. Cognitive decline severe enough to prevent informed consent is another reason to involve family and reconsider therapy goals.

Tapering Protocol

Abrupt discontinuation of testosterone enanthate is generally safe because the ester provides a slow-release depot, and one missed dose does not produce acute withdrawal. A reasonable taper for a patient on 100 mg weekly: reduce to 75 mg for 4 weeks, then 50 mg for 4 weeks, then stop. Check testosterone 4 weeks after cessation. If symptoms return and the patient and family want to resume, re-initiate at the lowest prior effective dose.

Life Expectancy and Goals of Care

In men with limited life expectancy (<2 years) due to advanced illness, continuing testosterone for symptom relief (energy, mood, appetite) may be reasonable even when standard monitoring thresholds are exceeded. This shifts from disease-prevention goals to comfort-oriented prescribing, which is a conversation best had explicitly rather than assumed.

Special Populations Within the Geriatric Bracket

Not all men over 65 are the same. A 66-year-old marathon runner and a 90-year-old with heart failure require fundamentally different approaches.

Men 65 to 74 in Good Health

This group most closely mirrors the T-Trials population and has the strongest evidence base. Standard geriatric dosing applies: start 50 to 100 mg weekly, target 400 to 600 ng/dL, monitor per protocol.

Men 75 and Older

Evidence thins considerably past 75. The Endocrine Society guideline makes no firm recommendation for or against therapy in this age group. If symptoms are clear and labs confirm deficiency, a trial at the lowest dose (50 mg weekly) with reassessment at 3 months is reasonable. If no measurable benefit is observed, stop.

Men With CKD Stage 3 or Higher

Testosterone enanthate is not directly nephrotoxic, but the erythropoietic effect can compound anemia management in CKD. Patients on erythropoiesis-stimulating agents (ESAs) may need ESA dose reductions when starting testosterone. The KDIGO guidelines recommend maintaining hemoglobin between 10 and 11.5 g/dL in CKD patients, a range easily exceeded when testosterone and ESAs are combined.